BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A validation study

Amber Louw; Vasiliki Panou; Weronika Maria Szejniuk; Christos Meristoudis; Siaw Ming Chai; Chris van Vliet; Y. C. Gary Lee; Ian M. Dick; Tina Firth; Louise Andersen Lynggaard; Azadeh Birbaneh Asghari; Mogens Vyberg; Johnni Hansen; Jenette Creaney; Oluf Dimitri Røe

doi:10.1016/j.jtho.2022.04.008

BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A validation study

Amber Louw, Vasiliki Panou, Weronika Maria Szejniuk, Christos Meristoudis, Siaw Ming Chai, Chris van Vliet, Y. C. Gary Lee, Ian M. Dick, Tina Firth, Louise Andersen Lynggaard, Azadeh Birbaneh Asghari, Mogens Vyberg, Johnni Hansen, Jenette Creaney^*, Oluf Dimitri Røe

^*Kontaktforfatter

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Originalsprog	Engelsk
Tidsskrift	Journal of Thoracic Oncology
Vol/bind	17
Udgave nummer	7
Sider (fra-til)	921-930
Antal sider	10
ISSN	1556-0864
DOI	https://doi.org/10.1016/j.jtho.2022.04.008
Status	Udgivet - jul. 2022

Bibliografisk note

Adgang til dokumentet

10.1016/j.jtho.2022.04.008Licens: CC BY 4.0

Andre filer og links

Link to publication in Scopus

Citationsformater

Louw, A., Panou, V., Szejniuk, W. M., Meristoudis, C., Chai, S. M., van Vliet, C., Lee, Y. C. G., Dick, I. M., Firth, T., Lynggaard, L. A., Asghari, A. B., Vyberg, M., Hansen, J., Creaney, J., & Røe, O. D. (2022). BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A validation study. Journal of Thoracic Oncology, 17(7), 921-930. https://doi.org/10.1016/j.jtho.2022.04.008

Louw, Amber ; Panou, Vasiliki ; Szejniuk, Weronika Maria ; Meristoudis, Christos ; Chai, Siaw Ming ; van Vliet, Chris ; Lee, Y. C. Gary ; Dick, Ian M. ; Firth, Tina ; Lynggaard, Louise Andersen ; Asghari, Azadeh Birbaneh ; Vyberg, Mogens ; Hansen, Johnni ; Creaney, Jenette ; Røe, Oluf Dimitri. / BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma : A validation study. I: Journal of Thoracic Oncology. 2022 ; Bind 17, Nr. 7. s. 921-930.

@article{c1a3ce97f58d414a8860abf15cc0f291,

title = "BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A validation study",

keywords = "BAP1, Chemotherapy, Pemetrexed, Pleural mesothelioma, Predictive biomarkers, Immunohistochemistry, Lung Neoplasms/pathology, Humans, Pleural Neoplasms/pathology, Australia/epidemiology, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Mesothelioma/pathology, Pemetrexed/therapeutic use, Platinum/therapeutic use, Mesothelioma, Malignant, Ubiquitin Thiolesterase, Tumor Suppressor Proteins",

author = "Amber Louw and Vasiliki Panou and Szejniuk, {Weronika Maria} and Christos Meristoudis and Chai, {Siaw Ming} and {van Vliet}, Chris and Lee, {Y. C. Gary} and Dick, {Ian M.} and Tina Firth and Lynggaard, {Louise Andersen} and Asghari, {Azadeh Birbaneh} and Mogens Vyberg and Johnni Hansen and Jenette Creaney and R{\o}e, {Oluf Dimitri}",

year = "2022",

month = jul,

doi = "10.1016/j.jtho.2022.04.008",

language = "English",

volume = "17",

pages = "921--930",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "Elsevier",

number = "7",

}

Louw, A, Panou, V , Szejniuk, WM , Meristoudis, C, Chai, SM, van Vliet, C, Lee, YCG, Dick, IM, Firth, T, Lynggaard, LA , Asghari, AB , Vyberg, M, Hansen, J, Creaney, J & Røe, OD 2022, 'BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A validation study', Journal of Thoracic Oncology, bind 17, nr. 7, s. 921-930. https://doi.org/10.1016/j.jtho.2022.04.008

BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma : A validation study. / Louw, Amber; Panou, Vasiliki ; Szejniuk, Weronika Maria ; Meristoudis, Christos; Chai, Siaw Ming; van Vliet, Chris; Lee, Y. C. Gary; Dick, Ian M.; Firth, Tina; Lynggaard, Louise Andersen ; Asghari, Azadeh Birbaneh ; Vyberg, Mogens; Hansen, Johnni; Creaney, Jenette; Røe, Oluf Dimitri.

I: Journal of Thoracic Oncology, Bind 17, Nr. 7, 07.2022, s. 921-930.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

TY - JOUR

T1 - BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma

T2 - A validation study

AU - Louw, Amber

AU - Panou, Vasiliki

AU - Szejniuk, Weronika Maria

AU - Meristoudis, Christos

AU - Chai, Siaw Ming

AU - van Vliet, Chris

AU - Lee, Y. C. Gary

AU - Dick, Ian M.

AU - Firth, Tina

AU - Lynggaard, Louise Andersen

AU - Asghari, Azadeh Birbaneh

AU - Vyberg, Mogens

AU - Hansen, Johnni

AU - Creaney, Jenette

AU - Røe, Oluf Dimitri

PY - 2022/7

Y1 - 2022/7

KW - BAP1

KW - Chemotherapy

KW - Pemetrexed

KW - Pleural mesothelioma

KW - Predictive biomarkers

KW - Immunohistochemistry

KW - Lung Neoplasms/pathology

KW - Humans

KW - Pleural Neoplasms/pathology

KW - Australia/epidemiology

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Mesothelioma/pathology

KW - Pemetrexed/therapeutic use

KW - Platinum/therapeutic use

KW - Mesothelioma, Malignant

KW - Ubiquitin Thiolesterase

KW - Tumor Suppressor Proteins

UR - http://www.scopus.com/inward/record.url?scp=85130555503&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2022.04.008

DO - 10.1016/j.jtho.2022.04.008

M3 - Journal article

C2 - 35489694

VL - 17

SP - 921

EP - 930

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 7

ER -

BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A validation study

Bibliografisk note

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater